Skip to main content
Fig. 8 | Journal for ImmunoTherapy of Cancer

Fig. 8

From: Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Fig. 8

Olaparib increases NK-mediated target cell lysis and ADCC in a diverse set of tumors. A variety of tumor types demonstrated increased NK cell-mediated lysis as measured by real-time impedance. a Lysis of estrogen receptor positive (ER+) breast carcinoma (MCF7) in the presence or absence of olaparib and NK, treated with cetuximab or isotype control. b Lysis of non-small cell lung carcinoma (NSCLC) (H460) in the presence or absence of olaparib and NK, treated with cetuximab, avelumab (ave) or isotype control. c Lysis of triple negative breast carcinoma (SUM149) in the presence or absence of olaparib and NK, treated with cetuximab (cet) or isotype control. d Lysis of chordoma (Ch22) in the presence or absence of olaparib and NK, treated with cetuximab, avelumab or isotype control. p < 0.01**, p < 0.001***, p < 0.0001****

Back to article page